Berberine containing therapy for initial Helicobacter Pylori eradicatio
Not Applicable
Recruiting
- Conditions
- H. pylori infection
- Registration Number
- JPRN-UMIN000034554
- Lead Sponsor
- Health bureau of Beijing
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with allergy history of drugs medicated in this trail Patients with history of hepatic or/and renal dysfunction Patients with history of operation on upper digestive tract Patients with alcoholism and drug abuse Patients in pregnancy or lactation Patients who ever participated other clinical trials in latest 3 months Patients with previous eradication therapy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eradication rate of H. pylori
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does berberine employ to inhibit Helicobacter pylori virulence factors like CagA or VacA?
How does berberine-containing therapy compare to standard triple/quadruple eradication regimens in H. pylori treatment efficacy and resistance profiles?
Which biomarkers (e.g., clarithromycin resistance genes, gastric pH levels) predict response to berberine-based H. pylori eradication protocols?
What are the potential adverse events of berberine in combination with PPIs and clarithromycin for H. pylori treatment?
How do berberine's anti-H. pylori properties synergize with amoxicillin or metronidazole in combination therapies?